What records are connected here?
- Evidence lanes
- 3
- Source years
- 15
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsLiver
Terlipressin is a lab-made analogue of the hormone vasopressin and the active ingredient in Terlivaz.1,2 FDA approved Terlivaz in 2022 to improve kidney function in adults with hepatorenal syndrome with a rapid loss of kidney function, a complication studied in people with cirrhosis.1,2 In the trial behind the approval, 29% of patients given terlipressin had their kidney failure reverse, compared with 16% given placebo. The label carries a boxed warning about serious or fatal respiratory failure.1
| What it is | A synthetic vasopressin analogue that acts mainly on vasopressin V1 receptors and is also converted in the body to lysine-vasopressin, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Terlivaz with an original approval date of September 14, 2022. The label has a boxed warning about serious or fatal respiratory failure.1,2 |
| Human evidence | One randomized, double-blind, placebo-controlled trial (CONFIRM) in 300 adults with hepatorenal syndrome, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Terlipressin is a synthetic analogue of vasopressin, a peptide hormone that acts on vasopressin V1 and V2 receptors.1
In the United States it is the active ingredient of Terlivaz, approved under NDA 022231, according to Drugs@FDA.2
The label states that terlipressin is about twice as selective for vasopressin V1 receptors as for V2 receptors, and that it acts both as a prodrug for lysine-vasopressin and on its own.1
It is thought to increase blood flow to the kidneys in hepatorenal syndrome by lowering pressure in the portal veins and raising effective blood volume and arterial pressure, according to the label.1
The label describes CONFIRM, a multicenter, double-blind, randomized, placebo-controlled trial in 300 adults with cirrhosis, fluid in the abdomen and rapidly worsening hepatorenal syndrome; 199 received terlipressin and 101 placebo, and both groups also received albumin.1
The main outcome was verified reversal of hepatorenal syndrome. It occurred in 58 of 199 patients (29.1%) given terlipressin and 16 of 101 (15.8%) given placebo, according to the label.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Terlivaz, application NDA 022231, with an original approval date of September 14, 2022.2
The Terlivaz label cited here (DailyMed SPL version 8, published October 26, 2026) states that it is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function, and that patients with very advanced kidney impairment are unlikely to benefit.1
The label carries a boxed warning that Terlivaz may cause serious or fatal respiratory failure, with higher risk in patients with volume overload or the most severe grade of acute-on-chronic liver failure.1
The label also states that it must not be used in patients with low blood oxygen or worsening breathing symptoms, or with ongoing reduced blood flow to the heart, limbs or intestines.1
How it compares with other treatments for hepatorenal syndrome: the trial described in the label compared terlipressin with placebo, with albumin in both groups.1
Its benefit beyond the population studied: the label limits the indication to adults with hepatorenal syndrome and rapid loss of kidney function.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Terlipressin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Terlipressin are a bounded selection, not every registration or paper about Terlipressin. For the years before Terlipressin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Terlipressin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Terlipressin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Terlivaz for hepatorenal syndrome. A randomized, placebo-controlled trial of 300 adults described in the label found more reversals of hepatorenal syndrome with terlipressin than with placebo. The label has a boxed warning about serious or fatal respiratory failure.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Terlivaz for hepatorenal syndrome. A randomized, placebo-controlled trial of 300 adults described in the label found more reversals of hepatorenal syndrome with terlipressin than with placebo. The label has a boxed warning about serious or fatal respiratory failure.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage.↗Source date November 9, 2026Literature metadata · added November 15, 2026
The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review.↗Source date November 4, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT06108362↗Source date October 13, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
29 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00089570 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00115947 at 2026-11-15T21:47:40.408Z. Its registry update date was 2006-03-09, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00369694 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-09-25, and PeptideScanner's reviewed identity mapping was terlipressin.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span March 9, 2006 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 38526204 in The American journal of gastroenterology as Journal Article, Randomized Controlled Trial, Equivalence Trial, Comparative Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41204083 in BMC anesthesiology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06108362 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was terlipressin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07252401 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was terlipressin.↗
Literature metadata
PubMed lists PMID 38353565 in Hepatology (Baltimore, Md.) as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-02-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41711944 in Pediatric nephrology (Berlin, Germany) as Journal Article, Review, with publication-date metadata of 2026-02-19 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 31941255 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Review, with publication-date metadata of 2019-12-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41200852 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-12 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07719933 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was terlipressin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06855758 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was terlipressin.↗
Literature metadata
PubMed lists PMID 33657294 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-03-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07304466 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was terlipressin.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026